Wednesday, December 19, 2012

Get Ripped with Marc "The Machine" Lobliner's New MTS Drop Factor

MTS Nutrition Drop Factor - The X Factor in fat loss has arrived!
The Fat Burner You Have Been Waiting For. No Fluff. No BS. Just proven results.

What in the world are you taking? Looking at the fat burners you have in your pantry, I am sure we can all say the same thing about the fat burners. Underdosed, proprietary blends that lead us to wonder what exactly we are taking. And the Latin names, wow! I actually looked up an ingredient from a well known fat burner and it literally translates to “Orange Tree”. No, not a special orange tree in Taiwan or a special extract from an orange tree, but actual ORANGE TREE! Like the ones you find in Florida that make that awesome juice. Well, orange juice is great and all, but will it cause fat loss?

As someone who wants results from a fat burner and the ability to control dosing to yield tremendous, tangible results above and beyond any fat burner in existence. A fat burner with ingredients you can look at, understand, and also KNOW that the dosing is scientifically validated. After years of researching and testing the most effective compounds in existence, MTS Nutrition CEO Marc Lobliner butted heads with some of the greatest science minds in the industry to create what they feel is the best fat burner for results, period. Drop Factor™ is here. FAST Fat loss; long-lasting, 12+ hour energy and TARGETED fat loss are the things that Drop Factor does better than any other fat burner ever seen, period. Are you ready for RESULTS?

The ingredients are max dosed with one caveat, Yohimbine HCl. Yohimbine HCl in its full dosing in Drop Factor, 2.5mg per serving, is usually very well tolerated. Some can take more, some less. Studies show that the effective dose is .2mg per kilogram of bodyweight per day—that is a LOT of Yohimbine HCl and too much for some people. Also, while the max dose of the other ingredients covers a wide range of weights and the two genders, Yohimbine HCl, being weight dependent, requires a varying degree of dosing and also, you need to ease into the higher dose moreso than other fat burning agents to assess tolerance. This is why EthiTech Nutrition, MTS Nutrition’s sister company, has a Yohimbine HCl so once you reach the maximum two capsules of Drop Factor two times per day, you can still adjust dosing by simply adding in Yohimbine HCl. It is the most though out fat loss system ever created!

Cocoa (Theobroma Cacao) Extract (Bean) standardized to 10% Theobromine: 500mg
Not only does this help decrease appetite and increase fat burning, it also acts as a vasodilator and diuretic (1). Not only will it aid in fat loss, but it will also provide that extra bloodflow and PUMP, a welcome effect while losing fat, alongside the reduction in nasty, excess water weight! Even cooler, it has even been linked to having an aphrodisiac effect! (2) All of this alongside a smooth, controlled stimulant release similar to caffeine make it a must have in any fat burner and with this adequate, no BS dosing, look out!

Caffeine: 250mg
The granddaddy of them all, Caffeine is the world’s most widely used stimulant (4). Caffeine is a Central Nervous System (CNS) stimulant that has been shown to reduce fatigue as well as mobilize fatty acids resulting in fat loss. (5)

Cayenne Pepper 40HU (Fruit): 150mg
Cayenne pepper increases thermogenesis (fat loss) by dilating blood vessels and increasing blood circulation. This helps to transport fatty acids and be BURNED! Cayenne Pepper is also use to aid digestion and relieve pain. (6)

Coleus Forskohlii Extract (Root) supplying 20% Forskolin (25mg): 125mg
Forskolin is the powerful active found in the herb Coleus forskohlii and can help increase lean mass (build muscle) and decrease fat mass (burn fat). Forskolin activates the enzyme adenylate cyclase, which increases cyclic adenosine monophosphate (cAMP) levels. The increase in cAMP activates hormone-sensitive lipase (HSL) which breaks down stored triglycerides (bodyfat) and releases fatty acids so they can be oxidized and body fat can be decreased.

Forskolin helps to increase the release of fatty acids from fat tissue allowing them to be burned for energy, leading to a decrease in body fat. (8)

Forskolin is also believed to have thyroid stimulating properties. Thyroid hormones are responsible for your metabolism. I have even known MANY fitness competitors who use this herb instead of harsh, prescription thyroid medications (when no pre-existing medical condition is present). Increasing thyroid output will accelerate your metabolic rate and lead to increased fat loss. (8)

To make things even more awesome, Forskolin may increase testosterone levels in men, but not negatively affect sex hormones in women. When on decrease calories, this can be A GREAT SIDE EFFECT and can also help explain how Forskolin prevents muscle wasting! (9)

Forskolin is a vasodilator. Blood flow is VITAL for fat loss as blood flow to fat tissue, especially stubborn fat areas, is vital to the transportation of fatty acids to areas where they can be burned and can help Yohimbine HCl (explained later) do it’s dirty work!

SyneLEAN™ Blend (containing Synephrine and Methylsynephrine): 45mg
Synephrine is found in the Citrus aurantium fruit. This fruit has been used for hundreds of years. Synephrine can increase metabolic rate and thermogenesis without any side effects on blood pressure or cardiovascular health. An increased metabolic rate means more calories are burned. Synephrine increases the body’s ability to metabolize stored body fat as well as a decrease in appetite. (10), (11)

Methylsynephrine is simply synephrine with a methyl group attached. Thus, it is absorbed very efficiently and we have found that our proprietary blend of the two forms of Synephrine leads to optimal appetite suppression and energy.

PolyphORAC Blend
(Grape Skin Extract [Seed and Skin], Blueberry Extract [Fruit], Raspberry Powder [Fruit], Cranberry Powder [Fruit], Prune Powder [Fruit], Cherry Powder [Fruit], Bilberry [Fruit] and Bilberry Extract [Fruit], Strawberry Powder [Fruit], Broccoli Extract [Whole], Spinach Powder [Whole], Tomato Powder [Whole], Carrot Powder [Whole], Onion Powder [Whole]): 25mg

Not only are antioxidants a pivotal component to overall health and wellness, but they also decrease the production of triglycerides thus decreasing fat storage and enhancing fat loss.

Anti-oxidants also increase fat used for energy during exercise, thus causing your body to burn more fat DURING exercise.

The PolyphOrac Blend was designed to contain a high amount of the anti-oxidants research shows to have a fat loss effect.

Vinpocetine: 5mg
Vinpocetine increases circulation and blood flow to the brain. This aids in the transport of fatty acids to be burned. Vinpocetine also helps with mental and cognitive enhancement. (12-49)

Black Pepper Fruit Extract (Bioperine): 5mg
Bioperine is a patented product from Sabinsa Corporation, U.S. Patents No. 5,536,506; 5,744,161; 5,972,382; 6,054,585.

Based on clinical data, having Bioperine in the digestive system with supplemented nutrients results in enhanced absorption. Studies show that when Bioperine is taken with other nutrients, it significantly increases the absorption of those nutrients. On its own, it may enhance the body's natural thermogenic activity and assist the digestive system with supplemented nutrients, resulting in enhanced absorption.

Yohimbine HCl: 2.5mg
Yohimbine is an alpha2 receptor antagonist and known to help LOSE FAT from PROBLEM AREAS like hips and thighs for women and lower back and love handles in men. This is VERY IMPORTANT as this is the variable we play with….

Yomhimbine blocks the alpha2 receptor, the receptor responsible for stubborn fat areas, from being activated. By blocking the alpha2 receptor with Yohimbine, the negative feedback caused by NE binding to the alpha receptors is reduced and fatty acid from those stubborn areas are released and now able to be burned. Yohimbine has been shown to increase fat loss by increasing the amount of lipid mobilization and oxidation and blood flow to adipose tissue due to alpha2 antagonism. So Yohimbine addresses two of the fat burning principles we are trying to address: alpha2 receptor action and blood flow. The presence of low insulin found on insulin controlling diets like makes Yohimbine work OPTIMALLY!

Thus, Drop Factor contains only 2.5mg Yohimbine HCl per serving. BUT, but adding in EthiTech Yohimbine HCl at the dosing needed for you, you will get the best results possible! The scientific dose is to work up to 0.2mg per kilo of bodyweight per day. This would be 18mg for a 200lb person. This would be a LOT in the formula, thus we give you this option and it allows you to work up to this dose. (50-109)

What about TRUTH TO LABEL!?!? Illegal Substances, Recalls?!

I have also heard of many effective fat burners removed from the market for having adulterated and/or ILLEGAL contaminants in their formulas, such as ADD medication, illegal amphetamines and even mislabeling for international shipping. Well, with Drop Factor you get what is on the label. Assurance guaranteed by…

With this assurance, each ingredient is tested going in for efficacy, microbials and truth to label. If your product does not have this on the label, don’t trust it! Not only will you burn tons of fat and feel great, but you will know what your are taking to help achieve that goal—nuff said!

MTS Nutrition Drop Factor References:
1) William Marias Malisoff (1943). Dictionary of Bio-Chemistry and Related Subjects. Philosophical Library. pp. 311, 530, 573. ISBN B0006AQ0NU.

2) Kenneth Maxwell (1996). A Sexual Odyssey: From Forbidden Fruit to Cybersex. New York: Plenum. pp. 38–40. ISBN 030645405X.

3) Joel Hardman & Lee Limbird, ed (2001). Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed.. New York: McGraw-Hill. p. 745. ISBN 0-07-135469-7.

4) Lovett, Richard (24 September 2005). "Coffee: The demon drink?". New Scientist (2518). Retrieved 2009-08-03.

5) Bolton, Sanford (1981). "Caffeine: Psychological Effects, Use and Abuse".Orthomolecular Psychiatry 10 (3): 202–211.

6) Ensminger AH, Esminger M. K. J. e. al. Food for Health: A Nutrition Encyclopedia. Clovis, California: Pegus Press; 1986 1986. PMID:15210.

7) Induction of Drug Metabolism by Forskolin, the Role of The Pregnane X Receptor and the PKA Signal Transduction Pathway.
J Pharmacol Exp Ther. 2004 Ding X, Staudinger J. University of Kansas.

8) Shonteh Henderson, Bahrat Magu, Chris Rasmussen, Stacey Lancaster, Chad Kerksick, Penny Smith, Charlie Melton, Patty Cowan, Mike Greenwood, Conrad Earnest, Anthony Almada, Pervis Milnor, Terri Magrans, Rodney Bowden, Song Ounpraseuth, Ashli Thomas, and Richard B Kreider, Effects of Coleus Forskohlii Supplementation on Body Composition and Hematological Profiles in Mildly Overweight Women, J Int Soc Sports Nutr. 2005; 2(2): 54–62. Published online 2005 December 9. doi: 10.1186/1550-2783-2-2-54

9) Obesity Research (2005) 13, 1335–1343; doi: 10.1038/oby.2005.162

10) Preuss HG et al. "Citrus aurantium as a thermogenic, weight-reduction replacement for ephedra: an overview." J Med. 33, 1-4:247-64, 2002.

11) Gougeon R et al. "Increase in the thermic effect of food in women by adrenergic amines extracted from citrus aurantium." Obes Res. 13, 7:1187-94, 2005.

12) Spilt A, Weverling-Rijnsburger AW, Middelkoop HA, et al. Late-onset dementia: structural brain damage and total cerebral blood flow. Radiology. 2005 Sep;236(3):990-5.

13) Szakall S, Boros I, Balkay L, et al. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. J Neuroimaging. 1998 Oct;8(4):197-204.

14) Szilagyi G, Nagy Z, Balkay L, et al. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci. 2005 Mar 15;229-230:275-84.

15) Vas A, Gulyas B, Szabo Z, et al. Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences. J Neurol Sci. 2002 Nov 15;203-204:259-62.

16) Wu SN. Large-conductance Ca2+- activated K+ channels:physiological role and pharmacology. Curr Med Chem. 2003 Apr;10(8):649-61.

17) Stolc S. Indole derivatives as neuroprotectants. Life Sci. 1999;65(18-19):1943-50.

18) Bonoczk P, Gulyas B, dam-Vizi V, et al. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull. 2000 Oct;53(3):245-54.

19) Lendvai B, Zelles T, Rozsa B, Vizi ES. A vinca alkaloid enhances morphological dynamics of dendritic spines of neocortical layer 2/3 pyramidal cells. Brain Res Bull. 2003 Jan 15;59(4):257-60.

20) Chiu PJ, Tetzloff G, Ahn HS, Sybertz EJ. Comparative effects of vinpocetine and 8-Br-cyclic GMP on the contraction and 45Ca-fluxes in the rabbit aorta. Am J Hypertens. 1988 Jul;1(3 Pt 1):262-8.

21) Jones OM, Brading AF, McC Mortensen NJ. Phosphodiesterase inhibitors cause relaxation of the internal anal sphincter in vitro. Dis Colon Rectum. 2002 Apr;45(4):530-6.

22) Truss MC, Stief CG, Uckert S, et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol. 2001 Nov;19(5):344-50.

23) Mancina R, Filippi S, Marini M, et al. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mol Hum Reprod. 2005 Feb;11(2):107-15.

24) Szapary L, Horvath B, Alexy T, et al. Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease. Orv Hetil. 2003 May 18;144(20):973-8.

25) Molnar P, Erdo SL. Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons. Eur J Pharmacol. 1995 Feb 6;273(3):303-6.

26) Bereczki D, Fekete I. A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur J Clin Pharmacol. 1999 Jul;55(5):349-52.

27) Karpati E, Biro K, Kukorelli T. Investigation of vasoactive agents with indole skeletons at Richter Ltd. Acta Pharm Hung. 2002;72(1):25-36.

28) Anon. Vinpocetine. Monograph. Altern Med Rev. 2002 Jun;7(3):240-3.

29) Hadjiev D. Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz. 2003 May 20;56(5-6):166-72.

30) Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc. 1987 May;35(5):425-30.

31) Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991;6(1):31-43.

32) Kemeny V, Molnar S, Andrejkovics M, Makai A, Csiba L. Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients. J Clin Pharmacol. 2005 Sep;45(9):1048-54.

33) Bonoczk P, Panczel G, Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur J Ultrasound. 2002 Jun;15(1-2):85-91.

34) Dezsi L, Kis-Varga I, Nagy J, Komlodi Z, Karpati E. Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke. Acta Pharm Hung. 2002;72(2):84-91.

35) Feigin VL, Doronin BM, Popova TF, Gribatcheva EV, Tchervov DV. Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur J Neurol. 2001 Jan;8(1):81-5.

36) Nagy Z, Vargha P, Kovacs L, Bonoczk P. Meta-analysis of Cavinton. Praxis. 1988 September 15;7(9):63-8.

37) Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;(1):CD003119.

38) Pereira C, Agostinho P, Oliveira CR. Vinpocetine attenuates the metabolic dysfunction induced by amyloid beta-peptides in PC12 cells. Free Radic Res. 2000 Nov;33(5):497-506.

39) Kiss B, Cai NS, Erdo SL. Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: evidence from release and ligand binding studies. Eur J Pharmacol. 1991 Dec 10;209(1-2):109-12.

40) Pilgramm M, Schumann K. Need for rheologically active, vasoactive and metabolically active substances in the initial treatment of acute acoustic trauma. HNO. 1986 Oct;34(10):424-8.

41) Konopka W, Zalewski P, Olszewski J, Olszewska-Ziaber A, Pietkiewicz P. Treatment results of acoustic trauma. Otolaryngol Pol. 1997;51 Suppl 25:281-4.

42) Maliavina US, Ovchinnikov I, Fasenko VP, et al. Cavinton prevention of neurosensory hypoacousis in patients with different forms of tuberculosis. Vestn Otorinolaringol. 2003;(3):35-40.

43) Qiu Y, Kraft P, Craig EC, Liu X, Haynes-Johnson D. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology. 2002 Jan;59(1):145-9.

44) Qiu Y, Kraft P, Craig EC, Liu X, Haynes-Johnson D. Identification and functional study of phosphodiesterases in rat urinary bladder. Urol Res. 2001 Dec;29(6):388-92.

45) Uckert S, Stief CG, Odenthal KP, et al. Comparison of the effects of various spasmolytic drugs on isolated human and porcine detrusor smooth muscle. Arzneimittelforschung. 1998 Aug;48(8):836-9.

46) Truss MC, Stief CG, Uckert S, et al. Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol. 2000 Dec;18(6):439-43.

47) Hampel C, Gillitzer R, Pahernik S, Melchior SW, Thuroff JW. Drug therapy of female urinary incontinence. Urologe A. 2005 Mar;44(3):244-55.

48) Alberti C. Bladder and cavernous contractility and relaxation among intracellular messengers, changes in sarcoplasmatic free calcium and phosphodiesterase activity. Arch Ital Urol Androl. 2000 Jun;72(2):75-82.

49) Tsuda K, Kinoshita Y, Nishio I. Synergistic role of progesterone and nitric oxide in the regulation of membrane fluidity of erythrocytes in humans: an electron paramagnetic resonance investigation. Am J Hypertens. 2002 Aug;15(8):702-8.

50) Starke K, Trendelenburg AU, Limberger N. Presynaptic a 2-adrenoceptors: subtype determination. In: "Adrenoceptors: Structure, Function, and Pharmacology", Ruffolo, RR ed. Harwood Academic Publishers. 1995:99-108.

51) Byland, DB. Subtypes of a 1- and a 2-adrenergic receptors. FASEB J 1992; 6:832-839.

52) Heible JP, Ruffolo RR, Starke K. Identification, characterization and subclassification of a 2-adrenoceptors: an overview. In: "a 2-Adrenergic Receptors: Structure, Function and Therapeutic Implications". Lanier SM, Limbird LE eds. Harwood Academic Press. 1997:1-18.

53) Raiteri M, Bonanno G, Maura G, et al. Subclassification of release-regulating a 2-autorecptors in human breain cortex. Br J Pharmacol 1992; 107:1146-1151.

54) Piascik MT, Smith MS, Edelmann SE, et al. a 2 and a 1-Adrenergic receptors in the regulation of peripheral vascular function. In: "a 2-Adrenergic Receptors: Structure, Function and Therapeutic Implications". Lanier SM and Limbird LE eds. Harwood Academic Publishers. 1997:171-178.

55) Trendelenburg AU, Limberger N, Rump LC. a 2-Adrenergic receptors of the a 2C subtype mediate inhibition of norepinephrine release in human kidney cortex. Mol Pharmacol 1994; 415:M68-M76.

56) Galitzky J, Larrouy D, Berlan M, Lafontan M. New tools for human fat cell alpha2A-adrenoceptor characterization. Identification on membranes and on intact cells using the agonist [3H]RX821002. J Pharmacol Exp Ther 1990; 252:312-319.

57) Lafontan M, Berlan M. Fat cell alpha2-adrenoceptors: the regulation of fat cell function and lipolysis. Endocr Rev 1995 Dec, 16(6):716-738.

58) Arner P, Kriegholm E, et al. Adrenergic regulation of lipolysis in situ at rest and during exercise. J Clinical Invest 1990; 85:893-898.

59) Maurige P, J Galitzky, M Berlan, M Lafontan. Heterogeneous distribution of beta and alpha-2 adrenoceptor binding sites in human fat cells from various fat deposits: functional consequences. Eur J Clin Invest 1987; 17:156-165.

60) Lafontan M, et al. Adrenergic regulation of adipocyte metabolism. Hum Reprod 1997 Oct; 12 Suppl 1:6-20.

61) Gether U, Lin S, Kobilka BK. Delineating ligand-specific structural changes in adrenergic receptors by use of fluorescence spectroscopy. In: "a 2-Adrenergic Receptors: Structure, Function and Therapeutic Implications". Lanier SM and Limbird LE eds. 1997. Harwood Academic Publishers. 1997: 31-42.

62) Hodgetts V, Coppack S, Frayn KN, Hockaday TDR. Factors controlling fat mobilization from human subcutaneous adipose tissue during exercise. J Appl Phys 1991; 71:445-451.

63) Millet L, Barbe M, Lafontan M, Berlan M, Galitzky J. Catecholamine effects on lipolysis and blood flow in human abdominal and femoral adipose tissue. J Appl Physiol 1998; 85(1):181-188.

64) Ruffolo RR, Bondinell W, Hieble JP. a - and b -Adrenoceptors: From the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem 1995; 38(19):3415-3444.

65) Arner P, Bolinder J. Microdialysis of adipose tissue. J Int Med 1991; 230:381-386.

66) Frayn KN, Fielding BA, Summers LKM. Investigation of human adipose tissue metabolism in vivo. J Endo 1997; 155:187-189.

67) Willette RN, Hieble JP, Sauermelch CF. The role of the alpha adrenoceptor subtypes in sympathetic control of the acralcutaneous microcirculation. J Pharmacol Exp Ther 1991; 256:599-605.

68) Borbujo J, Garcia-Villalon AL, Balle J, et al. Postjunctional alpha-1 and alpha-2 adrenoceptors in human skin arteries. An in vitro study. J Pharmacol Exp Ther 1989; 249:284-287.

69) Galitzky J, Lafontan M, Nordenstrom J, Arner P. Role of vascular alpha-2 adrenoceptors in regulating lipid mobilization from human adipose tissue. J Clin Invest 1993; 91:1997-2003.

70) Horn PT, Kohli JD, Listinsky JJ, Goldberg LI. Regional variation in the alpha-adrenergic receptors in the canine resistance vessels. Nauyn-Schmiedeberg’s Arch Pharmacol 1982; 318:166-172.

71) Flavahan NA, Cooke JP, Shepherd JT, Vanhoutte PM. Human postjunctional alpha-1 and alpha-2 adrenoceptors: differential distribution in arteries of the limbs. J Pharmacol Exp Ther 1987; 24:361-365.

72) Glusa E, Markwardt F. Characterization of postjunctional alpha-adrenoceptors in isolated human femoral veins and arteries. Nauyn-Schmiedeberg’s Arch Pharmacol 1983; 323:101-105.

73) Enoksson S, Nordenstrom J, Bolinder J, Arner P. Influence of local blood flow on glycerol levels in human adipose tissue. Int J Obesity 1995; 19:350-354.

74) Kovach AGB, Kovach E, Sandor P, et al. Metabolic responses to localized ischemia in adipose tissue. J Surg Res 1976; 20:37-44.

75) Barbe P, Galitzky J, Riviere D, Senard JM, et al. Effects of physiological and pharmaceutical variation of sympathetic nervous system on plasma non-esterified fatty acid concentrations in man. Br J Pharm 1993; 36:25-30.

76) Harmelen VV, Lonnqvist F, Thorne A, et al. Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocytes from obese subjects. Int J Obesity 1997; 21:972-979.

77) Arner P. Regulation of lipolysis in fat cells. Diab Rev 1996; 4:450-463.

78) Bjorntorp P. Obesity and the adipocyte. Neuroendocrine factors in obesity. J Endocrin 1997; 155:193-195.

79) Abate N, Garg A. Heterogeneity in adipose tissue metabolism: causes, implications, and management of regional adiposity. Prog Lipid Res 1995; 34:53-70.

80) Maurige P, et al. Regional difference in adipose tissue lipolysis from lean and obese women: existence of postreceptor alterations. Am J Physiol 1995 Aug; 269(2 pt 1): E341-E350.

81) Hellstrom L, Blaak E, Hagstrom-Toft E. Gender differences in adrenergic regulation of lipid mobilization during exercise. Int J Sports Med 1996; 17:439-447.

82) Goldberg MR Robertson D. Yohimbine: a pharmacological probe for study of the a 2-adrenoceptor. Pharmacol Rev 1983;35:143-180.

83) Berlan M, Galitzky J, Riviere D, et al. Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women. Int J Obesity 1991; 15:305-315.

84) Galitzky J, Taouis M, Berlan M, Riviere D, et al. a 2-Antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect oral yohimbine in healthy male volunteers. Eur J Clin Invest 1988; 18:587-594.

85) Galitzky j, Riviere D, Tran MA, Montastruc JL, Berlan M. Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers. Eur J Clin Pharmacol 1990; 39:447-451.

86) Kuchio C, Jonderdo K, Piskorska D. Does yohimbine act as a slimming drug? Isr J Med Sci 1991; 27:550-556.

87) Zahorska-Markiewiz B, Kuchio, Piskorska D. Adrenergic control of lipolysis and metabolic responses in obesity. Horm Metabol Res. 1986; 18:693-697.

88) Murburg MM, Villacres EC, Ko BN, Veith RC. Effects of yohimbine on human sympathetic nervous system function. J Clin Endocrin Metab 1991; 73:861-865.

89) Sax L. Yohimbine does not affect fat distribution in men. Int J Obesity 1991; 3:261-280.

90) Bulow J. Adipose tissue blood flow during exercise. Dan Med Bull 1983; 30:85-100.

91) Bulow J, Madsen J. Regulation of fatty acid mobilization from adipose tissue during exercise. Scand J Sports Sci 1986; 8:19-26.

92) Bulow J, Madsen J, Astrup A, Christensen NJ. Vasoconstrictor effect of high FFA/albumin ratios in adipose tissue in vivo. Acta Physiol Scand 1985; 125:661-667.

93) Berlan M, Montastruc JL, Lafontan M. Pharmacological prospects for a 2-adrenoceptor antagonist therapy. TiPS Rev 1992; 13:277-282.

94) Montastruc P, Belan M, Monstastruc JL. Effect of yohimbine on submaxiallary salivation in dogs. Br. J Pharmac 1989; 98:101-104.

95) Chatelut E, Rispail Y, Berlan M, Montastruc JL. Yohimbine increases human salivary secretion. Br J Clin Pharmac 1989; 366-368.)

96) Fiaramonti J, Berlan M, Fargeas MJ, Bueno L. Yohimbine stimulates colonic motility through a central action in conscious dogs. J Gastrointes Mot 1992; 4:137-141.

97) Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984; 41:751-763.

98) Murburg MM, Villacres EC, Ko BN, Veith RC. Effects of yohimbine on human sympathetic nervous system function. J Clin Endocrin Metab 1991; 73:861-865.

99) Grunhaus L, Tiongco D, Zelnik T, Flegel P, et al. Intravenous yohimbine. Selective enhancer of norepinephrine and cortisol secretion and systolic blood pressure in humans. Clin Neuropharmacol 1989; 12:106-114.

100) Henninger GR, Charney DS, Price LH. a 2-Adrenergic receptor sensitivity in depression. The plasma MHPG, behavioral and cardiovascular responses to yohimbine. Arc Gen Psychiatry 1988; 45:718-726.

101) McDougle CJ, Krystal JH, Price LH, Heninger GR, et al. Noradrenergic response to acute ethanol administration in healthy subjects: comparisons with intravenous yohimbine. Psychopharmacol 1995; 118:127-135.

102) Betz, JM, White KD. Gas chromatographic determination of yohimbine in commercial yohimbine products. J AOAC Int. 1995; 78:1189-1194.

103) Benedek IH, Blouin RA, McNamara PJ. Serum protein binding and the role of increased alpha1-acid glycoprotein in moderately obese subjects. Br J Clin Pharmacol 1984; 18:941-946.

104) Guthrie SK, Hariharan M, Grunhaus LJ. Yohimbine bioavailability in humans. Eur J Clin Pharmacol 1990; 39:409-411.

105) Hedner T, Edgar B, Edvinsson L, Hedner J, et al. Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. Eur J Clin Pharmacol 1992; 43:651-656.

106) Owen JA, Hakatsu SL, Fenemore J, Condra M, et al. The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol 1987; 32:577-582.

107) Le Verge R, Le Corre P, Chevanne F. Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. J Chromatog 1992; 574:283-292.

108) Brannan T, Martinez-Tica J, Yahr MD. Effect of yohimbine on brain monoamines: an in vivo study. J Neural Transm 1991; 3:81-87.

109) Hubbard JW, Pfister SL, Beidinger Am, Herzig TC, et al. The pharmacokinetic properties of yohimbine in the conscious rat. Naunyn-Schmiedeberg’s Arch Pharmacol 1988; 337:583-587.

110) University of Michigan Cardiovascular Center